Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 8/20 | 0.37 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | TNKS | O95271 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16699290 | 0.72 | CRHR1 (0.40) | CRHR1IDH1DDB1CRBNNPC1 | |
| SCHEMBL20909898 | 0.72 | RECQL (0.50) | CRHR1IDH1TYK2TNKS | |
| SCHEMBL2190750 | 0.72 | TNKS (0.36) | CRHR1IDH1CCR6TNKSPIK3CA | |
| SCHEMBL16699241 | 0.71 | CCNC (0.41) | CRHR1CCNCCDK8DDB1CRBN | |
| SCHEMBL15219419 | 0.71 | CCNC (0.41) | CRHR1CCNCCDK8DDB1CRBN | |
| SCHEMBL25043950 | 0.70 | SLC6A2 (0.37) | DDB1CRBN | |
| SCHEMBL9964663 | 0.69 | DGAT1 (0.40) | IDH1NPC1PKMRAB9A | |
| SCHEMBL22623648 | 0.69 | CRBN (0.55) | DDB1CRBN | |
| SCHEMBL16699036 | 0.69 | DDB1 (0.36) | IDH1DDB1CRBN | |
| SCHEMBL16699143 | 0.69 | GRM4 (0.40) | DDB1CRBNRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066094-B1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-08 | — | — | EP | disclosed |
| US-9890145-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-02-13 | — | — | US | disclosed |
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-27 | — | — | US | disclosed |
| EP-3066094-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | Takeda Pharmaceutical Company Limited (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9321757-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-26 | — | — | US | disclosed |
| WO-2015068856-A1 | PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311811-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | CRHR1 3772/4885IDH1 1481/4885CCNC 1871/4885 |
| US-20150133451-A1 | HETEROCYCLIC COMPOUND | IRAK4, IRAK1, IRAK2 | CRHR1 3772/4885IDH1 1481/4885CCNC 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.